Listed by the USPTO as MINCHELLA, KAITLYN L
Tech Center 1600 • Art Units: 1631 1672 1682 1685
This examiner grants 27% of resolved cases
MINCHELLA, KAITLYN L is assigned to Tech Center 1600 and Art Unit 1631. The profile includes 167 resolved cases, a 26.9% allowance rate, and a median of 1620 days to allowance. The interview lift is 20.7%, indicating a higher allowance outcome for cases associated with interviews in the reported data. Applicants may therefore evaluate interviews as one tool within a broader strategy for addressing difficult examination issues.
The principal companies are Tempus AI Inc., The Johns Hopkins University, and University of Maryland, Baltimore. The principal firms are Fox Rothschild LLP - JHU, Kilpatrick Townsend & Stockton LLP - West Coast, and LEYDIG VOIT & MAYER, LTD. The resolved-case volume provides context for the reported metrics, but individual outcomes will depend on claim scope and the application record. The median timing supports early planning for a prolonged prosecution path.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18118528 | Classifying User Activity Using Multiple Sensors | Final Rejection | Samsung Electronics Co., Ltd. |
| 17629327 | DETECTING NEURALLY PROGRAMMED TUMORS USING EXPRESSION DATA | Final Rejection | Genentech, Inc. |
| 18035067 | NETWORK APPROACH TO NAVIGATING THE HUMAN GENOME | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 19341734 | PLATFORMS, SYSTEMS, AND METHODS FOR PATHWAY OPTIMIZATION FOR PROCESS BOTTLENECKS IN SYNTHETIC BIOLOGY DEVELOPMENT | Non-Final OA | X Development LLC |
| 18450468 | SYSTEMS AND METHODS FOR IDENTIFYING SEQUENCE VARIATION ASSOCIATED WITH GENETIC DISEASES | Non-Final OA | LIFE TECHNOLOGIES CORPORATION |
| 17842893 | CELL-FREE DNA FOR ASSESSING AND/OR TREATING CANCER | Final Rejection | The Johns Hopkins University |
| 17204892 | CELL-FREE DNA FOR ASSESSING AND/OR TREATING CANCER | Final Rejection | The Johns Hopkins University |
| 17982399 | SYSTEMS AND METHODS FOR MULTI-LABEL CANCER CLASSIFICATION | Non-Final OA | Tempus AI, Inc. |
| 17571412 | SYSTEMS AND METHODS FOR JOINT LOW-COVERAGE WHOLE GENOME SEQUENCING AND WHOLE EXOME SEQUENCING INFERENCE OF COPY NUMBER VARIATION FOR CLINICAL DIAGNOSTICS | Final Rejection | Tempus AI, Inc. |
| 17150992 | SYSTEMS AND METHODS FOR MULTI-LABEL CANCER CLASSIFICATION | Final Rejection | Tempus AI, Inc. |
| 16732229 | TRANSCRIPTOME DECONVOLUTION OF METASTATIC TISSUE SAMPLES | Final Rejection | TEMPUS AI, INC. |
| 17859974 | SYSTEM, METHOD, AND APPARATUS FOR PREDICTING GENETIC ANCESTRY | Non-Final OA | Mars, Incorporated |
| 17590659 | System, Method and Computer Simulation Environment For In Silico Trials in Pre-Diabetes and Type 2 Diabetes | Final Rejection | University of Virginia Patent Foundation |
| 18133798 | SYSTEMS AND METHODS FOR GENERATING A GENOTYPIC CAUSAL MODEL OF A DISEASE STATE | Non-Final OA | KPN INNOVATIONS, LLC. |
| 17725354 | Genome Feature Extraction Method, Disease Prediction Method, Apparatus and Device | Non-Final OA | Alibaba (China) Co., Ltd. |
| 18248529 | MULTIPLE INSTANCE LEARNING FOR PEPTIDE-MHC PRESENTATION PREDICTION | Non-Final OA | NEC Laboratories Europe GmbH |
| 15926977 | SYNTHETIC MULTIPLETS FOR MULTIPLETS DETERMINATION | Final Rejection | Becton, Dickinson And Company |
| 18401532 | DETECTION DEVICE AND DETECTION METHOD | Final Rejection | SHIMADZU CORPORATION |
| 17597760 | SYSTEMS AND METHODS FOR CELL OF ORIGIN DETERMINATION FROM VARIANT CALLING DATA | Non-Final OA | Roche Sequencing Solutions, Inc. |
| 15489658 | METHODS FOR DISTINGUISHING INFLAMMATORY BOWEL DISEASES USING MICROBIAL COMMUNITY SIGNATURES | Final Rejection | UNIVERSITY OF MARYLAND, BALTIMORE |
| 16666210 | HIGHLY SENSITIVE TRANSPLANT REJECTION SURVEILLANCE USING TARGETED DETECTION OF DONOR SPECIFIC CELL FREE DNA | Non-Final OA | The Medical College of Wisconsin, Inc |
| 17502661 | METHOD AND APPARATUS FOR PROVIDING INFORMATION ASSOCIATED WITH IMMUNE PHENOTYPES FOR PATHOLOGY SLIDE IMAGE | Final Rejection | LUNIT Inc. |
| 18556328 | MACHINE LEARNING BASED HISTOPATHOLOGICAL RECURRENCE PREDICTION MODELS FOR HPV+ HEAD / NECK SQUAMOUS CELL CARCINOMA | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17838115 | METHOD AND SYSTEM FOR IMPROVED MANAGEMENT OF GENETIC DISEASES | Final Rejection | Alexion Pharmaceuticals, Inc. |
| 18311385 | Artificial selection approach for improving secondary microbial functions using a partner organism | Non-Final OA | The Trustees of Boston College |
| 16721619 | CELL-FREE DNA END CHARACTERISTICS | Final Rejection | GRAIL, Inc. |
| 17006124 | SYSTEMS AND METHODS FOR DETERMINING CONSENSUS BASE CALLS IN NUCLEIC ACID SEQUENCING | Final Rejection | GRAIL, LLC |
| 18254534 | GENOMIC GRAVE AND FUNERAL SYSTEM FOR CREATION OF GENOMIC GRAVE | Non-Final OA | Individual inventor |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy26.9% of resolved applications examined by Kaitlyn L Minchella were allowed (167 resolved cases), compared with 28.0% across Art Unit 1631 over the last five years.
This examiner's interview lift is +20.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Kaitlyn L Minchella took 1,620 days on average from filing to allowance.
Kaitlyn L Minchella examines applications in Art Unit 1631 in Tech Center 1600 (Biotechnology & Pharmaceuticals).